Introduction
============

Osteoporosis (OP) is a common bone disorder that increases the risk of fractures and is characterized by low bone mass ([@b1-mmr-18-01-0067],[@b2-mmr-18-01-0067]). OP can be classified into primary, secondary and idiopathic types. Primary OP typically affects postmenopausal women and senile men, and is therefore further divided into postmenopausal OP and senile OP ([@b3-mmr-18-01-0067]). OP that occurs in young males with absence of secondary causes of bone loss is termed male idiopathic osteoporosis (MIO) ([@b4-mmr-18-01-0067]). OP results from an imbalance between bone formation by osteoblasts and bone absorption by osteoclasts ([@b5-mmr-18-01-0067]). Decreased recruitment of osteoblasts and failure of vitamin D activation were demonstrated to be associated with senile OP ([@b6-mmr-18-01-0067]). Estrogen deprivation is the primary cause of postmenopausal OP and also serves a role in senile OP ([@b7-mmr-18-01-0067]). Although MIO is an important public health problem worldwide ([@b8-mmr-18-01-0067]), the pathogenesis of MIO differs from the other two types of OP and has not yet been elucidated. However, evidence indicates that osteoblastic defects may lead to MIO ([@b9-mmr-18-01-0067]) and that the insulin-like growth factor I (IGF-I) pathway, and alterations in sex hormones and sclerostin production, also serve roles in the pathogenesis of MIO ([@b9-mmr-18-01-0067]--[@b11-mmr-18-01-0067]). To develop accurate and effective diagnosis and treatment strategies for MIO, the molecular mechanisms underlying the development of this disease requires investigation.

Differentially expressed genes (DEGs) were previously reported to be associated with the pathogenesis of OP, and RNA sequencing is an approach that has been used to identify DEGs in numerous diseases, including OP ([@b12-mmr-18-01-0067]). Using RNA sequencing, the DEGs in patients with MIO, and senile and postmenopausal OP, compared with normal controls (NCs), were identified. DEGs that were common among these three types of OP and unique DEGs only present in patients with MIO were further analyzed. Functional annotation was performed and a protein-protein interaction (PPI) network was constructed to further investigate the biological functions of DEGs in OP. To the best of our knowledge, the present study is the first to identify DEGs in patients with MIO by RNA-sequencing. The results of the present study may be used in the future for identification of genes and pathways associated with MIO and aid in elucidating the pathogenesis of this disease.

Materials and methods
=====================

### Patients

Patients with OP (2 patients with senile OP, 2 patients with postmenopausal OP and 2 patients with MIO) and two NC patients were recruited from June to August 2016 at Jining No. 1 People\'s Hospital (Jining, China). Characteristics of patients with MIO and healthy NC patients are presented in [Table I](#tI-mmr-18-01-0067){ref-type="table"}. Written informed consent was obtained from all participants and the present study was approved by the Ethics Committee of Jining No. 1 People\'s Hospital (Jining, China).

### RNA isolation and sequencing

Whole blood samples were obtained from all eight participants. Total RNA was isolated from whole blood samples and purified using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and an RNeasy Mini kit (Qiagen, Inc., Valencia, CA, USA), respectively. The quantity and integrity of purified RNA was verified using an Agilent 2100 Bioanalyzer (Agilent Technologies, Inc., Santa Clara, CA, USA). mRNA that passed quality control (RNA integrity number \>7) was used to construct libraries with a TruSeq RNA Sample Prep kit v2 (Illumina, Inc., San Diego, CA, USA), as described below. Initially, mRNA was fragmented at 95°C for 8 min with fragmentation buffer. Subsequently, the fragmented mRNA samples were used as templates for the synthesis of the first cDNA strand using First Strand Master Mix and Super Script II reverse transcriptase (Invitrogen; Thermo Fisher Scientific, Inc.) at 25°C for 10 min, 42°C for 50 min and 70°C for 15 min. The second cDNA strand was synthesized following the addition of Second Strand Master Mix and incubation at 16°C for 1 h. Finally, end repair, adenylate 3′ ends and adapter ligation were performed according to the manufacturer\'s protocol of the TruSeq RNA Sample Prep kit v2. Polymerase chain reaction (PCR) was performed with PCR Master Mix and RNA PCR primer cocktail in the TruSeq RNA Sample Prep kit v2 (Illumina, Inc., San Diego, CA, USA) to amplify the libraries according to the manufacturer\'s instructions. The following thermocycling conditions were used for the PCR: Initial denaturation at 98°C for 30 sec; 11 cycles of 98°C for 10 sec, 65°C for 30 sec and 72°C for 15 sec, followed by a final extension step of 72°C for 10 min. The enriched cDNA libraries were subsequently sequenced using the Illumina HiSeq 2500 (Illumina, Inc.) sequencing platform.

### Identification of DEGs

Read QC tool in FastQC version 0.11.4 software ([@b13-mmr-18-01-0067]) was used for the quality control of FASTQ data. Trimming of raw data was performed with cutadapt version 1.9.1 ([@b14-mmr-18-01-0067]). Low quality reads, including adaptor sequences and reads with ratios of N base \>10%, were removed and clean reads were obtained. TopHat version 2.1.1 ([@b15-mmr-18-01-0067]) was used to align the clean reads to the human genome (GRCh38.p7 assembly, <https://www.ncbi.nlm.nih.gov/assembly/GCF_000001405.38>) ([@b16-mmr-18-01-0067]). The quantification of mRNA and standardized output was performed using Cuffquant and Cuffdiff in Cufflinks version 2.2.1 ([@b15-mmr-18-01-0067]). Fragments per kilobase of exon per million fragments mapped were used to determine the transcript abundance of each gene. P\<0.05 and abs (count_1-count_2) \>100 served as the thresholds for the identification of DEGs, where abs indicated the absolute value, and count_1 and count_2 indicated the cases of OP (senile, postmenopausal and MIO) and the control group, respectively. The DEGs in MIO, and postmenopausal and senile OP, compared with NCs were identified. DEGs that were common among the three types of OP were identified. A heat map of DEGs in MIO and common DEGs in the three types of OP were generated using the heat map.2 function in the gplots package in R version 3.3.3 ([@b17-mmr-18-01-0067]).

### Functional annotation

Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed using the online software GeneCodis 3 (<http://genecodis.cnb.csic.es/analysis>) ([@b18-mmr-18-01-0067]) to interpret the biological function of DEGs in MIO, postmenopausal OP and senile OP. A false discovery rate (FDR) \<0.05 was considered to indicate a statistically significant difference.

### PPI network construction

To determine disease-associated pathways and functions of proteins at the molecular level, the PPI networks of DEGs in MIO, and postmenopausal and senile OP, were constructed using Biological General Repository for Interaction Datasets (<http://thebiogrid.org/>) and Cytoscape version 3.3.3 ([@b19-mmr-18-01-0067]). Nodes were used to represent proteins and edges to represent interactions between proteins. Based on Cytoscape version 3.3.3, proteins with a degree of \>160 were defined as hub proteins of the PPI network.

Results
=======

### Identification of DEGs

Compared with NCs, a total of 519 (185 upregulated and 334 downregulated), 368 (272 upregulated and 96 downregulated) and 1,472 (646 upregulated and 826 downregulated) DEGs were identified in MIO, senile OP and postmenopausal OP, respectively. The top 20 upregulated and downregulated DEGs in MIO are presented in [Table II](#tII-mmr-18-01-0067){ref-type="table"}.

A total of 138 shared DEGs were identified in the three types of OP compared with NCs. A total of 7 DEGs, including α-hemoglobin stabilizing protein (AHSP), carbonic anhydrase 1 (CA1), hemoglobin subunit δ (HBD), transmembrane and coiled-coil domain family 2 (TMCC2), joining chain of multimeric IgA and IgM (JCHAIN), RP2 ARL3 GTPase-activating protein (RP2) and S100 calcium-binding protein P (S100P), were differentially expressed in MIO compared with both senile and postmenopausal OP ([Table III](#tIII-mmr-18-01-0067){ref-type="table"}). Certain DEGs, including AHSP, CA1, HBD and TMCC2, were downregulated in MIO but upregulated in senile and postmenopausal OP, compared with NCs. A heat map of the top 100 DEGs in MIO is presented in [Fig. 1](#f1-mmr-18-01-0067){ref-type="fig"}, while a heat map of the 138 common DEGs among the three types of OP is presented in [Fig. 2](#f2-mmr-18-01-0067){ref-type="fig"}.

### Functional annotation

According to the GO enrichment analysis, 'RNA metabolic process' (FDR=5.60×10^−11^), 'mRNA metabolic process' (FDR=8.59×10^−11^), 'cytoplasm' (FDR=9.85×10^−36^), 'cytosol' (FDR=5.98×10^−34^), 'protein binding' (FDR=4.02×10^−49^) and 'ATP binding' (FDR=2.55×10^−13^) were the most significantly enriched GO terms of DEGs in MIO ([Fig. 3](#f3-mmr-18-01-0067){ref-type="fig"}). 'Peptidyl-serine phosphorylation' (FDR=1.37×10^−5^), 'protein phosphorylation' (FDR=2.43×10^−5^), 'cytoplasm' (FDR=1.82×10^−8^), 'nucleus' (FDR=8.03×10^−7^), 'protein binding' (FDR=4.30×10^−11^) and 'ATP binding' (FDR=3.33×10^−8^) were the most significantly enriched GO terms of the 138 common DEGs among the three types of OP (data not shown).

Following KEGG enrichment analysis, 'MAPK signaling pathway' (FDR=9.25×10^−4^), 'type I diabetes mellitus' (FDR=2.19×10^−3^), 'antigen processing and presentation' (FDR=2.42 ×10^−3^) and 'hematopoietic cell lineage' (FDR=2.53×10^−3^) were determined to be the most significantly enriched pathways in MIO ([Fig. 4](#f4-mmr-18-01-0067){ref-type="fig"}). Four DEGs including T-cell antigen CD7 (CD7), T-cell surface glycoprotein CD3 ε chain (CD3E), T-cell surface glycoprotein CD5 (CD5) and major histocompatibility complex class II antigen DR β 1 (HLA-DRB1) in MIO were significantly enriched in the 'hematopoietic cell lineage' pathway. In addition, 'hematopoietic cell lineage' (FDR=6.71×10^−9^), 'graft-versus-host disease' (FDR=1.84×10^−5^) and 'allograft rejection' (FDR=1.98×10^−5^) were the most significantly enriched in senile OP ([Fig. 5](#f5-mmr-18-01-0067){ref-type="fig"}), while 'spliceosome' (FDR=3.79×10^−12^), 'protein processing in endoplasmic reticulum' (FDR=3.83×10^−12^) and 'endocytosis' (FDR=4.41×10^−12^) were the most significantly enriched pathways in postmenopausal OP ([Fig. 6](#f6-mmr-18-01-0067){ref-type="fig"}). 'Hematopoietic cell lineage' was a significantly enriched pathway that was common among all three types of OP ([Figs. 4](#f4-mmr-18-01-0067){ref-type="fig"}--[6](#f6-mmr-18-01-0067){ref-type="fig"}).

### PPI network construction

The PPI network of the top 20 upregulated and downregulated DEGs in MIO was constructed, which included 1,066 nodes and 1,246 edges ([Fig. 7](#f7-mmr-18-01-0067){ref-type="fig"}). According to the PPI network, α-synuclein (SNCA; degree, 179; clustering coefficient, 0), CDC-like kinase 1 (CLK1; degree, 162; clustering coefficient, 0) and receptor tyrosine-protein kinase erbB-2; degree, 160; clustering coefficient, 0) were the 3 hub proteins in MIO. The PPI network of the 138 common DEGs among the three types of OP consisted of 2,680 nodes and 3,957 edges (data not shown). Heat shock protein 90 α family class B member 1 (degree, 233; clustering coefficient, 2.22×10^−4^), capping actin protein of muscle Z-line α subunit 2 (degree, 229; clustering coefficient, 6.51×10^−4^) and CLK1 (degree, 162; clustering coefficient, 1.53×10^−4^) were the 3 hub proteins. CLK1 was a common hub protein in the MIO-specific PPI network and OP-specific PPI network.

Discussion
==========

MIO is an important public health problem worldwide ([@b8-mmr-18-01-0067]) and the mechanism underlying this disease remains to be elucidated. The present study identified DEGs in MIO, and senile and postmenopausal OP, compared with NCs. The common DEGs among these three types of OP and unique DEGs only identified in patients with MIO were investigated. The primary symptom of OP is bone loss induced by an imbalance between bone resorption and bone formation. Factors that regulate this balance may be involved in the pathogenesis of OP. Osteoblastic defects have been reported to be associated with the mechanism underlying the development of MIO, and regulators of osteoblasts and bone formation may therefore be associated with MIO.

'MAPK signaling pathway' was a significantly enriched pathway of DEGs in patients with MIO included in the present study. The mitogen-activated protein kinase (MAPK) pathway regulates numerous cellular activities, including cell proliferation, differentiation, survival, death and transformation ([@b20-mmr-18-01-0067]). The MAPK signaling pathway primarily consists of an extracellular signal-regulated kinase, p38 and c-Jun NH~2~-terminal protein kinase (JNK) ([@b21-mmr-18-01-0067]). Furthermore, the JNK signaling pathway was reported to be associated with the differentiation and proliferation of osteoblasts ([@b22-mmr-18-01-0067]--[@b25-mmr-18-01-0067]). The MAPK signaling pathway and the DEGs enriched in this pathway may serve a role in MIO by regulating bone formation.

Previous studies have demonstrated that IGF-I, which has a similar function and structure to insulin, is crucial for the progression of MIO ([@b10-mmr-18-01-0067],[@b26-mmr-18-01-0067]). In the present study, DEGs in patients with MIO were significantly enriched in 'type I diabetes mellitus'. As a deficiency in insulin can impair bone formation induced by osteoblasts, type I diabetes mellitus (TIDM) with low serum IGF-I levels has been reported to be a risk factor for OP ([@b27-mmr-18-01-0067]). Therefore, we hypothesized that the TIDM pathway and its associated DEGs in MIO, including perforin 1, major histocompatibility complex (HLA) class I C, HLA class II DQα1, HLA class II DRβ1, HLA class II DQβ1, may serve a role in MIO by regulating bone formation via IGF-I. Furthermore, HLA alleles have been reported to be associated with OP by regulating bone mineral density ([@b28-mmr-18-01-0067]).

In addition to genes involved in the regulation of bone formation by osteoblasts, genes involved in the process of bone resorption by osteoclasts may also be associated with the regulation of bone formation and the mechanism of MIO. Osteoclasts originate from pluripotent hematopoietic cells ([@b5-mmr-18-01-0067]). In the present study, four DEGs (CD7, CD3E, CD5 and HLA-DRB1) in MIO were significantly enriched in the 'hematopoietic cell lineage' pathway, which supported the hypothesis that the number and activity of osteoclasts may be associated with MIO. Furthermore, 'hematopoietic cell lineage' was a common pathway enriched in the other two types of OP, which emphasizes the potential importance of this pathway in OP.

Tetraspanin (TSPAN)5 is a member of the TSPAN family of proteins and was a unique DEG in MIO that was not differentially expressed in the other two types of OP. TSPAN5 was previously reported to be an inhibitor of osteoclastogenesis ([@b24-mmr-18-01-0067]). In the present study, downregulated TSPAN5 was detected in the blood of patients with MIO, which indicated that TSPAN5 may be involved in the process of MIO as reduced TSPAN5 levels leads to the promotion of osteoclastogenesis.

SNCA was another unique DEG in the present study, which was identified only in patients with MIO. SNCA has been demonstrated to be associated with osteoclastogenesis and bone resorption ([@b28-mmr-18-01-0067]) by interacting with the bone morphogenetic protein pathway and modulating bone loss induced by deficiency of estrogen ([@b29-mmr-18-01-0067]--[@b31-mmr-18-01-0067]). In the present study, SNCA was downregulated in patients with MIO and may serve a role in the development of this disease by regulating bone resorption. Furthermore, SNCA was a hub gene in the MIO-specific PPI network, which emphasizes the potential that this gene may be associated with the pathogenesis of MIO.

In the present study, CLK1 was a hub protein of both the MIO- and OP-specific PPI networks. CLK1 is a dual specificity kinase ([@b31-mmr-18-01-0067]) and was upregulated in all three types of OP, which indicates that CLK1 may regulate the process of OP. However, to the best of our knowledge, an association between CLK1 and OP has not been previously reported. Further studies are required to validate the function of CLK1 in the pathogenesis of OP.

Of the 138 common DEGs in all three types of OP, 7 DEGs (AHSP, CA1, HBD, TMCC2, JCHAIN, RP2 and S100P) were significantly differentially expressed in MIO compared with the other two types of OP. Compared with NCs, CA1 was significantly downregulated in MIO, while it was upregulated in both senile and postmenopausal OP. As a member of the CA family, CA1 has been reported to function in bone formation, bone remodeling and calcification ([@b32-mmr-18-01-0067]). CA1 catalyzes the hydration and dehydration reactions of CO~2~/H~2~CO~3~. As CaCO~3~ is associated with initial bone formation, CA1 contributes to bone formation and biomineralization by forming a CaCO~3~ precipitate ([@b32-mmr-18-01-0067],[@b33-mmr-18-01-0067]). Increased CA1 activity was demonstrated to promote bone resorption ([@b34-mmr-18-01-0067]). Although the mechanism remains to be elucidated, the hydrogen ions produced by CA1 can dissolve the mineral components of bones and may enhance bone resorption ([@b34-mmr-18-01-0067]). By regulating calcification, CA1 serves different roles in bone resorption and formation. As the expression of CA1 in MIO was significantly different compared with the other two types of OP in the present study, it may be hypothesized that CA1 may be involved in the process of MIO by regulating bone mass and that the mechanism may be different compared with that in senile and postmenopausal OP. Further experiments are required to verify this hypothesis.

In the current study, S100P was upregulated in all three types of OP compared with NC. However, the expression of S100P in MIO was markedly decreased compared with senile and postmenopausal OP. S100P is a member of the S100 family of calcium-binding proteins and is a target of bone morphogenetic protein 4 ([@b35-mmr-18-01-0067]). Furthermore, abnormal calcium binding was previously reported to be associated with OP ([@b36-mmr-18-01-0067]), which indicates that S100P may serve a unique role in MIO.

In conclusion, the MAPK signaling pathway and the TIDM pathway may be associated with the process of MIO by regulating bone formation. Furthermore, the hematopoietic cell lineage pathway and two unique DEGs in MIO (SNCA and TSPAN5) may be associated with bone resorption. CA1 and S100P may regulate the process of MIO via functions in calcification and dysregulation of calcium binding. In the present study, CA1 was downregulated in MIO and upregulated in senile and postmenopausal OP, which indicates a unique role for this protein in MIO. However, a lack of biological validation of the results of the current study was a limitation. Further validation with a larger sample sizes, as well as *in vitro* and *in vivo* experiments are required to confirm these results.
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###### 

Patient characteristics.

                            MIO        Postmenopausal OP   Senile OP   Normal control
  ------------------------- ---------- ------------------- ----------- ----------------
  No. of patients           2          2                   2           2
  Male/female               2/0        0/2                 2/0         2/0
  Age (years)               38.0±1.0   73±5.0              89±0.0      33.5±1.5
  Smoking history (n)       2          0                   0           0
  Alcohol consumption (n)   2          0                   0           2

Data are presented as the mean ± standard deviation. MIO, male idiopathic osteoporosis.

###### 

Top 20 downregulated and upregulated differentially expressed genes in patients with male idiopathic osteoporosis compared with normal controls.

  A, Downregulated genes                
  -------------------------- ---------- -------------
  212                        ALAS2      5.00×10^−5^
  2038                       EPB42      5.00×10^−5^
  25793                      FBXO7      5.00×10^−5^
  2766                       GMPR       5.00×10^−5^
  3047                       HBG1       5.00×10^−5^
  3048                       HBG2       5.00×10^−5^
  3117                       HLA-DQA1   5.00×10^−5^
  3123                       HLA-DRB1   5.00×10^−5^
  3136                       HLA-H      5.00×10^−5^
  55796                      MBNL3      5.00×10^−5^
  9172                       MYOM2      5.00×10^−5^
  8991                       SELENBP1   5.00×10^−5^
  6521                       SLC4A1     5.00×10^−5^
  6535                       SLC6A8     5.00×10^−5^
  6622                       SNCA       5.00×10^−5^
  7145                       TNS1       5.00×10^−5^
  25893                      TRIM58     5.00×10^−5^
  10098                      TSPAN5     5.00×10^−5^
  7280                       TUBB2A     5.00×10^−5^
  220001                     VWCE       5.00×10^−5^
                                        
  **B, Upregulated genes**              
                                        
  **Gene ID**                **Gene**   **P-value**
                                        
  84188                      FAR1       5.00×10^−5^
  9103                       FCGR2C     5.00×10^−5^
  84641                      MFSD14B    5.00×10^−5^
  253260                     RICTOR     5.00×10^−5^
  9765                       ZFYVE16    5.00×10^−5^
  1824                       DSC2       1.00×10^−4^
  3311                       HSPA7      1.00×10^−4^
  2790                       GNG10      1.50×10^−4^
  6670                       SP3        2.00×10^−4^
  23325                      KIAA1033   2.50×10^−4^
  50640                      PNPLA8     2.50×10^−4^
  6201                       RPS7       2.50×10^−4^
  19                         ABCA1      3.50×10^−4^
  167227                     DCP2       4.00×10^−4^
  1195                       CLK1       5.00×10^−4^
  1668                       DEFA3      5.00×10^−4^
  100113407                  TMEM170B   5.00×10^−4^
  80124                      VCPIP1     5.00×10^−4^
  6189                       RPS3A      5.50×10^−4^
  54790                      TET2       5.50×10^−4^

NCBI, National Center for Biotechnology Information.

###### 

Differentially expressed genes in MIO compared with NCs and senile and postmenopausal OP.

  Gene ID (NCBI)   Gene     P-value 1     P-value 2     P-value 3     Differential expression
  ---------------- -------- ------------- ------------- ------------- -------------------------
  51327            AHSP     5.00×10^−5^   5.00×10^−5^   5.00×10^−5^   Downregulated
  759              CA1      1.00×10^−4^   5.00×10^−5^   5.00×10^−5^   Downregulated
  3045             HBD      1.50×10^−4^   5.00×10^−5^   5.00×10^−5^   Downregulated
  3512             JCHAIN   1.12×10^−2^   4.15×10^−3^   1.50×10^−4^   Upregulated
  6102             RP2      9.45×10^−3^   3.48×10^−2^   2.20×10^−2^   Upregulated
  6286             S100P    2.95×10^−3^   4.59×10^−2^   6.00×10^−4^   Upregulated
  9911             TMCC2    1.00×10^−4^   2.50×10^−4^   5.00×10^−5^   Downregulated

P-value 1 represents comparisons between the MIO and the NC groups, P-value 2 represents comparisons between the MIO and senile OP groups, and P-value 3 represents comparisons between the MIO and postmenopausal OP groups. The differential expression column represents the upregulation or downregulation of each gene in MIO samples compared with NCs. MIO, male idiopathic osteoporosis; NCs, normal controls; OP, osteoporosis; AHSP, α-hemoglobin stabilizing protein; CA1, carbonic anhydrase 1; HBD, hemoglobin subunit δ; JCHAIN, joining chain of multimeric IgA and IgM; RP2, RP2 ARL3 GTPase-activating protein; S100P, S100 calcium-binding protein P; TMCC2, transmembrane and coiled-coil domain family 2; NCBI, National Center for Biotechnology Information.
